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Introduction 
 Despite weighing barely more than an ounce, the tiny butterfly-shaped thyroid gland is a vital 
metabolic regulator of the endocrine system.  The body depends on this tissue of thyroid cells to produce 
a unique set of hormone products that perfuse throughout the body to maintain homeostatic metabolic 
function; the importance of this unassuming collection of cells cannot be underestimated.  The thyroid 
gland controls the rate at which every cell, tissue, and organ in the body functions, from your muscles, 
bones, and skin to your digestive tract, brain, heart, and more. It does this primarily by secreting 
hormones that control how fast and efficiently cells convert nutrients into energy—a 
chemical activity known as metabolism—so that the cells can perform their functions1.  In seamless 
coordination with other glands within the endocrine system, most people never have to worry about the 
ramifications arising from a defective thyroid.  However, a malfunctioning thyroid, either overactive or 
underactive, can lead to two general disorders aptly named hyperthyroidism and hypothyroidism, 
respectively.  These disorders can be manifested by a variety of pathological processes through which 
they affect the body during fetal development, childhood, and adulthood.  Although thyroid disorders can 
be inherited or induced prior to birth by influence from the mother’s endocrine system, problems with the 
thyroid are commonly developed later in life.  The medical science community has developed a variety of 
diagnostic tests to measure the effectiveness of the thyroid’s activities by simple blood hormone level 
analysis.  Treatments for thyroid disorders have been developed whereby the general procedure for 
dealing with an overactive thyroid is through surgical thyrectomy or antithyroid drugs, and treating low 
thyroid hormonal levels is done through synthetic hormonal replacement pharmaceuticals on a cost-
effective level.  In addition, a number of pharmaceutical companies now produce the thyroid hormone 
generically under a variety of names.  Approximately 6 percent1 of the U.S. population is affected with a 
thyroid disorder, a number that is likely larger due to misdiagnosis or symptomatic oversight domestically 
while potentially higher rates may be prevalent overseas.  Because of the vital role the thyroid plays 
within the human body, thyroid disorders are important and relevant in nearly all medical disciplines.  
 This paper is by no means an exhaustive review or ‘stand-in’ encyclopedia for all there is to know 
about thyroid disorders.  Instead, as all science is a compilation and synthesis derived from a 
collaboration among disciplines, this paper will reflect this trend by analyzing thyroid disorders from 
biological, histological, medical, and pharmaceutical sources; this will accomplish several objectives.  
First, a natural progression of information on treatment, from disorder detection to medical intervention, 
will be employed.  My aim is for the reader to be presented with a logical succession of biological 
information so that the implications of thyroid malfunction are more deeply appreciated.  Because 
medicine requires the integration of different spheres of insight, a medical disorder involving the thyroid 
is most properly understood by observing the problem at every level.  Second, the perspectives on thyroid 
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disorders gained from varying disciplines will allow for a fuller, richer description of the intricacies of the 
endocrine system as a whole.  This approach parallels my own science education in that I have 
scholarship in physiology, molecular biology, histology, and metabolism – in short, never do I examine a 
biological process by utilizing only one approach within the expansive realm of biology.  No process can 
be happening on the macroscopic scale without a microscopic explanation and vice versa.  Third, I find 
this project interesting, challenging, and relevant for a person both diagnosed with hypothyroidism and 
attending medical school in several months.   
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I. The Endocrine System and the Thyroid 
Function 
 The endocrine system is a complex assortment of cells, tissues, and organs which work to 
maintain homeostasis within the body.  No matter what level of organization a particular endocrine 
component possesses, the business of the cells is to produce and secrete endocrine hormones within their 
surrounding interstitial fluids where closely associated capillaries take up these hormones for transport to 
their target cells.  The cells of the endocrine system are marked by the appearance of numerous 
intracellular vacuoles and granules which contain the plentitude of hormones being secreted.  Endocrine 
components do not contact duct systems like their exocrine counterparts thereby necessitating the 
proximate access to the cardiovascular system2.  These hormones are carried by the circulatory system to 
cells throughout the body, including the nervous system in some cases.  Some endocrine hormones affect 
many different types of cells throughout the body like growth hormones and of course, thyroid hormones.  
Other hormones have specific activities which activate a unique set of cells; for instance, ovarian 
hormones only affect the female sex organs as well as influencing the secondary sexual characteristics of 
the female body3.   
Hormones come in a variety of molecular ‘flavors’ generally classified into three broad 
categories: proteins and polypeptides, steroids, and derivatives of amino acids and arachidonic acid 
analogs2.  Major organs of the endocrine system include the hypothalamus, anterior and posterior 
pituitary, thyroid, adrenal medulla and cortex, and pancreas.  Other organs that are not generally 
considered part of the endocrine system but have endocrine characteristics because they secrete hormones 
into the circulatory system are the heart, kidney, stomach, small intestines, testes, and ovaries.  The 
hormones secreted by the endocrine system have varying degrees of time intervals between stimulus and 
secretion, the duration of action, and concentration which are governed via positive and negative feedback 
systems; superimposed on the negative and positive feedback control of hormone secretion are periodic 
variations in hormone release that are influenced by seasonal changes, various stages of development and 
aging, the diurnal cycle, and sleep3. 
 The action of the endocrine system is to ensure the proper regulation of metabolism, growth, 
nutrient uptake, sexual development, and tissue maintenance.  The hypothalamus-pituitary axis located 
just below the brain is responsible for a wide range of hormones that go on to stimulate multiple organs of 
the endocrine system.  For instance, by acting on the adrenal cortex, adrenocorticotropin (ACTH) controls 
the secretion of some of the adrenocortical hormones which affect the metabolism of glucose, proteins, 
and fats; thyroid stimulating hormone (TSH) controls the rate of secretion of thyroxine and 
triiodothyronine by the thyroid gland, and these hormones control the rates of most intracellular chemical 
reactions, as will be elucidated later3.  The anterior pituitary also secretes growth hormones which 
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promote the ‘growth’ of the entire body by affecting protein formation, cell multiplication, and cell 
differentiation3.  The ovaries and testes of the female and male, respectively, are responsible for all of the 
sexual development and maintenance within the body through secretion of estrogen under control of 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) for females and testosterone in males, 
also under regulation by LH.  The parathyroid secretes a product which regulates the deposition and 
degradation of bone.  While this is certainly not a comprehensive list of endocrine system functions, the 
importance of these activities is quite clear – without these pathways functioning properly, it is easy to see 
that the body can deteriorate quite quickly if the problem is not addressed because these hormones act 
throughout the entire body.   
The Thyroid 
 Among the major players of the endocrine system, the thyroid has been studied extensively for its 
paramount importance in maintaining a healthy, normal-functioning, bodily metabolism.  The thyroid 
gland, located immediately below the larynx on each side of and anterior to the trachea, is one of the 
largest of the endocrine glands, normally weighing 15-20 grams (0.5-0.7 oz.)3 see Figure 1.  The thyroid 
is under control of the anterior pituitary gland which secretes thyroid-stimulating hormone (TSH); the 
anterior pituitary gland’s secretion of TSH is itself regulated by thyrotropin-releasing hormone (TRH) 
secreted by the hypothalamus see Figure 2.   When the thyroid receives TSH, this stimulates the cells 
within the thyroid to begin producing triiodothyronine (T3) and thyroxine (T4); as a portion of cellular 
hormonal output, T4 makes up about 93 per cent but is less potent in effectiveness whereas T3 makes up 
the remaining 7 per cent but is more potent3.  While T4 is produced in much greater quantities, both 
hormones are converted and used as T3 within the recipient systemic tissues.  The production pathways of 
the two hormones are dependent upon ingested iodine.  Combined with tyrosine, which is uniquely used 
as a substrate via a process that will be described later in this paper, T3 and T4 are ready to be released 
into the bloodstream to act on tissue throughout the body to regulate metabolism.  T3 and T4 are capable 
of imparting a negative feedback effect on the anterior pituitary’s secretion of TSH (i.e., shutting off the 
‘thermostat’) but inhibiting further release of TSH when T3 and T4 levels are low. 
 As the hormones circulate throughout the body within the blood plasma, slowly some of the T4 is 
converted into T3 so that about 35 µg of T3 is available for cellular uptake under normal conditions3.  To 
be transported within the blood, thyroid hormones are bound to the plasma protein thyroxine-binding 
globulin and sometimes thyroxine-binding prealbumin and albumin.  The thyroid hormones are then 
slowly released from these proteins to the surrounding tissue cells and actually stored within the systemic 
cells.  Once within the cells, thyroid hormones activate nuclear receptors at specific thyroid hormone 
response elements on the DNA like retinoid X receptor (RXR)3, increase the number and activity of 
mitochondria, increase active transport of ions through cell membranes, increase the rate of carbohydrate 
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use and absorption, regulate protein synthesis and degradation, regulate fat synthesis and degradation, 
influence body and tissue growth, and regulate the development of the nervous system in the fetus and 
young child. 
 Diseases of the thyroid can be grouped into two major categories: hyperthyroidism and 
hypothyroidism.  Hyperthyroidism, as the name implies, is characterized by an overactive thyroid and the 
causes can be manifested in several ways with the end result being an overproduction of T3 and T4; this 
can be caused by hypertrophy of the thyroid gland by which a greater thyroid mass entails more cells to 
produce the active hormones and also by an overproduction of TSH either through overstimulation of the 
anterior pituitary through abnormal TRH levels or ineffective T3/ T4 negative feedback mechanisms.  A 
variety of diseases are known to contribute to these conditions.  Most of the symptoms expected of one 
with hyperthyroidism are related to a higher than normal basal metabolic rate which when sustained over 
a long period of time can be very detrimental to the body.  Specific symptoms include excitability, 
intolerance to heat, increased sweating, mild to extreme weight loss, diarrhea, muscle weakness, 
nervousness or other psychic disorders, extreme fatigue but inability sleep, and tremor of the hands3.  
Conversely, hypothyroidism in many ways can be considered the polar opposite of hyperthyroidism and 
is characterized by insufficient T3 and T4 levels in the body thereby manifesting as a below normal basal 
metabolic rate.  Theoretically, hypothyroidism could be caused by a variety of physiological conditions in 
which TRH and TSH levels are low causing low T3 and T4 blood levels but it seems most hypothyroid 
disorders are caused by defects within the thyroid itself.  Interestingly, autoimmune attack on the thyroid 
is one of the leading causes of hypothyroidism; the immune attack on the thyroid causes sustained 
inflammation around the thyroid and eventually the thyroid cells are destroyed leading to decreased T3 
and T4 production potential4.  Occasionally, the thyroid can swell causing a condition called a goiter.  
This condition sometimes arises because the patient does not receive enough iodine in their diet to 
synthesize the thyroid hormones.  Consequently, with no thyroid hormone being produced, the negative 
feedback effect on the anterior pituitary gland is non-existent so the elevated TSH levels stimulate 
copious amounts of substrates involved in the synthesis process which accumulate within the cells 
causing them to swell, but without a subsequent release of normal thyroid hormone.  Symptoms of 
hypothyroidism are characteristic of below normal basal metabolic rate.  More specifically, these include 
fatigue and excessive sleeping, extreme muscular sluggishness, slowed heart rate, decreased cardiac 
output, decreased blood volume, increased body weight, constipation, mental sluggishness, depressed hair 
growth, dryness of the skin, and potential edematous appearance throughout the body3. 
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II. Physiology 
The Endocrine System 
 The primary goal of the endocrine glands are to produce hormones within their tissue and then 
release the hormonal products into closely coordinated blood vessels so that the hormones can be 
dispersed throughout the body and act on the appropriate organs which have specific receptors to specific 
hormones.  Because the endocrine glands are ductless, and they depend upon the blood vessels for 
hormonal delivery, they are accordingly very vascular.  Not only do these hormones act through the blood 
stream to be transported to cells elsewhere in the body, but they may also function to send signals to 
adjacent cells (paracrine control) and to themselves (autocrine control)2.  Once a hormone reaches its 
destination, to fulfill its duty it must activate some sort of specific receptor located either on the cell 
surface or within the cell, usually in the nucleus.  Cell surface receptors interact with peptide hormones or 
catecholamines (i.e. epinephrine) that cannot penetrate the cell due to their hydrophilic, polar nature.  
Nuclear receptors, like those involved with thyroid hormone pathways and steroids, are activated by 
hormones that can travel through the cell membrane and are usually multiprotein complexes that contain 
three binding domains: a hormone-binding region, a DNA-binding region, and an amino-terminal region2.  
In general, when a hormone binds the hormone-binding region of the receptor, this induces an allosteric 
transformation which promotes binding of RNA transcriptional machinery so that a particular set of genes 
can be expressed.  Conversely, hormone binding could also ‘silence’ a particular gene or set of genes by 
promoting repression through a variety of means, namely heterochromatin formation or by allosterically 
blocking replication machinery.  These competing effects create a delicate regulation balance in which 
specific hormone interactions can promote diverse gene activity.  This process will be discussed in greater 
detail in the Molecular Analysis section. 
The Thyroid and Coordinated Organs 
The Hypothalamus 
Located at the base of the brain, the almond-sized hypothalamus dictates the activity of the 
pituitary gland along with many other functions of the endocrine system as well as the autonomic nervous 
system because most physiological and psychological stimuli that reach the brain also affect the 
hypothalamus2.  The hypothalamus helps regulate blood pressure, body temperature, anger, circadian 
rhythms, fluid and electrolyte balance, body weight, thirst and appetite.  Aside from steroidal and 
hormonal stimuli, the hypothalamus is capable of integrating olfactory stimuli like pheromones, neural 
stimuli from organs and the central nervous system, daylight, and the presence of blood-borne pathogens3.  
When appropriate, the neurons of the hypothalamus function to stimulate release of signaling peptides 
that will be transported to the anterior pituitary through the pars distalis where they will stimulate the cells 
of the anterior pituitary to release a specific hormone, TSH being one of them.  Via the posterior pituitary 
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gland, the hypothalamus is able to regulate oxytocin and antidiuretic hormone (ADH) levels, but the 
signal from the hypothalamus is transmitted to the posterior pituitary through nerve impulses rather than 
by a peptide intermediate2.  Not surprisingly, the hypothalamus is under a tightly controlled feedback loop 
by which circulating hormones produced by the pituitary and affected organs travel through the body and 
help turn on or off stimulatory impulses for hypothalamic regulatory peptides.   
The Anterior Pituitary Gland 
The anterior pituitary gland is of great importance to the proper functioning of the thyroid.  The 
posterior pituitary gland has no direct effect upon the thyroid and thus will not be discussed.  The 
pituitary gland itself is a pea-sized, compound endocrine gland weighing between 0.5 and 1.5 g, which is 
centrally located at the base of the brain where it lies in a saddle-shaped depression and is connected by a 
short, vascular stalk called the infundibulum to the hypothalamus2.  The gland is split up into two lobes, 
the anterior and posterior, characterized by glandular epithelial tissue and neural secretory tissue, 
respectively.  The anterior pituitary gland is generally classified as being comprised of a pars distalis 
which forms the bulk of the anterior lobe, the pars intermedia which is a thin portion near the posterior 
portion of the lobe, and the pars tuberalis which forms a sheath around the infundibulum.  Like all 
endocrine glands, the anterior pituitary is surrounded by blood vessels forming a complex meshwork of 
capillaries.  One such capillary system that is of utmost importance to the ‘communication’ between the 
hypothalamus and the anterior pituitary gland is the hypothalamohypophysial portal system; this capillary 
network provides a portal vein connection by which hormonal signals from the hypothalamus can reach 
the anterior pituitary gland.   
The cells of the anterior lobe of the pituitary gland are organized in clumps and cords which are 
separated by fenestrated sinusoidal capillaries of relatively large diameter2.  These cells are under direct 
control by hormones synthesized and released from the hypothalamus.  Six anterior pituitary hormones 
are produced that will circulate throughout the systemic vasculature and effect the cells of other endocrine 
glands.  Adrenocorticotropic hormone (ACTH) affects the adrenal cortex, follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) affect the ovaries and testes, and of course thyroid-stimulating 
hormone (TSH) affects the thyroid.  These four hormones are generally referred to as tropic hormones.  In 
addition, the anterior pituitary is capable of producing growth hormone (GH) which is utilized by all the 
cells of the body and prolactin (PRL) which influences mammary gland lactation and female sex organ 
contractions.  These hormones are produced by highly specialized cells that secrete only their designated 
hormone-type.  ACTH is produced by corticotropes, FSH and LH by gonadotropes, TSH by thyrotropes, 
GH by somatotropes, and PRL by lactotropes2.   
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The Thyroid 
The thyroid is one of the largest of the endocrine glands despite it small relative size to the entire 
human body.  It is readily recognized by its bi-lobed structure connected by a thin isthmus that crosses 
over the anterior of the trachea and is contained within a thin connective tissue capsule see Figure 3.  The 
functional unit of the thyroid gland is the follicle formed by a special spherical ordering of the cuboidal 
epithelial thyroidal cells called the follicular epithelium see Figure 4.  Hundreds of thousands of follicles 
that vary in diameter from about 0.2 to 1.0 mm constitute nearly the entire mass of the gland2.  These 
follicular epithelial cells, as their cuboidal histology suggests, are especially adept at secretory functions 
and secrete a protein-rich substance called colloid which stores a large glycoprotein called thyroglobulin 
(discussed in Human Development) and the synthesized thyroid hormone intermediates and products.  
The follicular epithelium is comprised of follicular cells, also known as principal cells, which are 
responsible for T3 and T4 production and parafollicular cells, also known as C cells, which lie away from 
the follicle lumen and secrete calcitonin which regulates calcium metabolism.  Calcitonin and its effects 
will not be discussed in this paper.   
Despite having dimensions that are only 5 cm in length and 2.5 cm in width2 (each lobe), the 
gland is so important that it receives a blood flow about five times the weight of the gland each minute3 
which is greater than the kidney, adrenal cortex, and sometimes, when there is a goiter, blood flow in the 
gland may be heard with a stethoscope, known as a bruit5.  T3 and T4 are liberated from thyroglobulin 
within the colloid follicles by lysosomal action with T4 being the much more prevalent thyroid hormone 
form by an order of 20:1; only the follicular cells are capable of producing T4, whereas most T3  which is 
five times more active, is produced through conversion of T4 within the kidney, liver, and heart2.  Upon 
being released from thyroglobulin the hormones must cross back through the follicular epithelium, 
through the basal membrane, and then enter the closely associated blood vessels and lymphatic vessels.  
These hormones are quickly taken up and bound to by various blood specific proteins – thyroxin-binding 
protein, prealbumin, with only a small portion remaining that will circulate freely within the systemic 
vasculature and activate negative feedback loops.  The body is able to recycle some tyrosine and iodide 
which are freed from breakdown of thyroid hormones within the cytoplasm after being taken up by cells.   
Hyperthyroidism 
 Macrophysiology and Pathology 
 Hyperthyroidism is marked by elevated levels of T3 and T4 circulating throughout the body.  The 
increase in T3 and T4 can be caused by a number of malfunctions within the hypothalamus-anterior 
pituitary-thyroid interaction. In general, the underlying cause of all hyperthyroidism is overstimulation of 
the thyroid follicles by which they receive a constant signal to produce hormones.  The majority of 
hyperthyroidism cases are attributed to Graves’ disease1. 
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Responsible for 50 to 80 percent of hyperthyroid cases, and affecting 0.5 percent of the U.S. 
population, Graves’ disease is the result of circulating IgG antibodies that bind to and activate the G-
protein–coupled thyrotropin receptor. This activation stimulates follicular hypertrophy and hyperplasia, 
causing thyroid enlargement, as well as increases in thyroid hormone production and the fraction of T3 
relative to T4 in thyroid secretion (approximately 20 percent to 30 percent)6.  Normally in Graves’ 
disease, the TRH level is found to be lower than normal.  This is quite logical as elevated T3 and T4 levels 
in the blood will necessarily inhibit the release of TRH from the hypothalamus because of the 
aforementioned negative feedback loop.  Lower TRH will necessarily translate into lower TSH levels, but 
the T3 and T4 levels are offset due to the constant stimulation from autoimmune attack.  Triggers of 
Graves’ disease in persons with genetic susceptibility to the disease include stressful life events, infection, 
and recent childbirth7. Several associated genetic loci have been identified, conferring susceptibility to 
Graves’ disease alone or to both Hashimoto’s thyroiditis and Graves’ disease8.   
 Other illnesses that are known to be synonymous with hyperthyroidism are painless thyroiditis, 
painful subacute thyroiditis, toxic thyroid adenoma, toxic multinodular goiter, and iodine-induced 
hyperthyroidism1.   Painless thyroiditis is usually only temporary and has high occurrence postpartum.  
Painful subacute thyroiditis is similar to painless thyroiditis except that the thyroid is very tender to the 
touch and triggering events are usually viral infections which elevate immune activation that can lead to 
auto-thyroid attack.  Toxic thyroid adenoma refers to a tumor within the thyroid in which the follicular 
cells become cancerous and thus they rapidly divide subsequently producing copious amount of T3 and 
T4.  Like toxic thyroid adenoma, toxic multinodular goiter is indicated by several nodules within the 
thyroid causing enlarged size, hence the ‘goiter’, and these nodules have an elevated risk of becoming 
cancerous6.  Finally, abnormal iodine-levels can cause both hyperthyroidism and hypothyroidism; the 
effect of iodine on thyroid hormone product is discussed in Human Development.     
Symptoms and Organ Systems Affected 
 The characteristic symptom of Graves’ disease is Graves’ ophthalmopathy.  Characterized by 
bulging eyes and inflammation around the eyes, this is clinically visible in approximately 30 percent to 50 
percent of patients with Graves’ disease see Figure 5.  Other symptoms include weight loss despite 
increased appetite and dietary intake, heat intolerance, difficulty sleeping, tremor, increased frequency of 
defecation, proximal-muscle weakness, irritability, and menstrual irregularity. Signs include tachycardia, 
stare, eyelid lag, goiter, resting tremor, hyperreflexia, and warm, moist, and smooth skin6.  Older patients 
usually do not experience the tachycardia that younger patients do but experience more symptoms of 
weight loss.  Interestingly, because the thyrotropin (TSH) receptor is expressed in the human thymus, 
overstimulation of the thyrotropin receptor by anti–thyrotropin-receptor antibodies may enhance thymus 
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growth in patients with Graves’ disease9.  The result of thymus overstimulation is hypercalcemia which is 
elevated calcium levels in the blood.   
The non-Graves’ diseases have similar symptoms that are indicative of hyperthyroidism. A 
patient may experience any of these symptoms in varying degrees of severity: enlarged thyroid gland, 
heat intolerance, exhaustion, emotional changes (insomnia, irritability, anxiety that is sometimes mixed 
with depression), nervousness, excessive perspiration, elevated respiration, excessive thirst, excessive 
hunger, weight loss, racing and irregular heartbeat, fast pulse, hand tremors, muscle weakness, diarrhea, 
eye problems, lighter menstrual periods, infertility, and hives1.   
Because thyroid hormone plays such an important metabolic role, the digestive system and 
correlated metabolic activity is profoundly affected.  Elevated T3 and T4 leads to rapid uptake of glucose, 
enhance glycolysis and gluconeogenesis, increased absorption, and increased insulin production.  The 
effects upon fat metabolism change in a parallel fashion: lipids are mobilized rapidly from the fat tissue, 
free fatty acid concentration in the blood plasma elevates while cholesterol, phospholipids, and 
triglycerides drop, and there is a high degree of fatty acid oxidation to compensate for the increased 
metabolic activity associated with increased basal metabolic rate.  Because there is such a drive for 
metabolic reactions throughout the body, the requirement for vitamins is elevated to serve as cofactors 
and coenzymes and often times a vitamin deficiency can result2.  In addition to the above mentioned 
tachycardia and irregular heartbeat, increased thyroid hormone actually increases the strength of heart 
contractions.   
Hypothyroidism 
 Macrophysiology and Pathology 
 Naturally, hypothyroidism is marked by decreased levels of T3 and T4 circulating throughout the 
body.  In hyperthyroid patients, the therapies used to treat the overactive thyroid usually result in a 
hypothyroid state as the treatment for hypothyroid is both simpler and less harsh for the patient’s body.  
Aside from hyperthyroid-turned-hypothyroid patients, the most common cause of hypothyroidism is 
Hashimoto’s Thyroiditis.  While thyroiditis can lead to stimulation in the case of hyperthyroidism, 
thyroiditis in relation to hypothyroidism refers to the progressive deterioration and eventual lack of 
hormonal potential by the thyroid tissue as a result of continual inflammatory damage – this is precisely 
the case in Hashimoto’s Thyroiditis4.  Another trigger to hypothyroidism is radiation treatment for neck 
and head cancers which can lead to the damage of thyroid tissue thereby decreasing thyroid hormone 
output.  Sometimes when the thyroid malfunctions, hormone secretion is blocked and this can lead to a 
greatly enlarged thyroid gland as hormone is trapped within the follicles.  This leads to the emergence of 
a goiter which is visible clinically as a large lump in the neck in the vicinity of the thyroid1.  Several so-
called ‘anti-thyroid’ drugs cause goiters and consequently a lack of circulating T3 and T4 leading to 
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hypothyroidism.  One family of drugs are thiocyanate ions, perchlorate ions, and nitrate ions which 
decrease iodide trapping by competitive binding to the iodide pumps whereby iodine cannot be 
sufficiently taken up into the thyroid and thyroid hormones cannot be synthesized2; because of decreased 
thyroid hormone, the anterior pituitary tries to compensate by secreting elevated levers of TSH which 
causes hypertrophy in the thyroid gland leading to a goiter.  Propylthiouracil, methimazole, and 
carbimazole prevent formation of thyroid hormone by blocking the union of iodides and tyrosine leading 
to a similar feedback response that arises from iodine pump inhibition.  In addition, excessive levels of 
iodide in the thyroid can actually inhibit proper thyroid function and cause goiter formation. Hypothyroid 
events can arise postpartum and when the pituitary gland fails to both receive TRH stimulation from the 
hypothalamus or is not able to secrete TSH to promote adequate thyroid hormone production.  Finally, 
several studies have shown that eating disorders, particularly bulimia and anorexia nervosa, can lead to a 
condition known as euthyroid sick syndrome characterized by depressed T3 and T4 levels despite an 
otherwise healthy thyroid gland10.  Patients diagnosed with hypothyroidism likely have a combination of 
these causes, with general dysfunction of the thyroid tissue or insufficient TSH release being the main 
culprits.  Speaking for myself, being diagnosed with hypothyroidism, I was never tested for Hashimoto’s 
disease, but simply tested for hypothyroidism and treated accordingly – from personal experience and 
acquaintances, most people fall into this category.   
Symptoms and Organ Systems Affected  
Despite the varied causes of hypothyroidism, the symptoms of autoimmune thyroiditis, goiter, 
radiation damage, surgical removal, or anti-thyroid drug therapy are all the same and for the most part are 
the opposite of hyperthyroidism. The physiological effects of thyroid hormone deficiency are constant 
tiredness (known as somnolence with sleeping up to 14 hours a day), cold intolerance, muscle 
sluggishness, loss of appetite, weight gain, bradycardia, anemia, decreased cardiac output, decreased 
blood volume, light headedness, depression, dry skin, brittle fingernails, decreased hair growth and hair 
loss, constipation, joint pain, heavier menstrual periods, and high cholesterol.  An interesting condition 
that can arise when a patient has total lack of thyroid hormone is the state of myxedema.  This condition 
results in large quantities of hyaluronic acid and chondroitin sulfate bound with protein to form excessive 
tissue gel in the interstitial spaces causing extreme bagginess under the eyes and swelling of the face2.  In 
older persons with hypothyroidism, some symptoms are particularly risky – especially because of the 
impact elevated cholesterol levels have in leading to atherosclerosis.  Other common symptoms particular 
to older patients are congestive heart failure, psychosis, dementia, and loss of balance which can be 
particularly dangerous if the patient has brittle bones. 
A point of interest that is worth mentioning before moving on to issues surrounding thyroid 
functioning in human development is the effect smoking has upon thyroid health.  Studies have shown 
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that smoking may protect against the development of thyroid peroxidase antibodies, which may result in a 
decreased risk of Hashimoto’s hypothyroidism, whereas it stimulates the development of Graves’ 
hyperthyroidism11.  Consequently, while patients are universally urged to quit smoking, the absence of 
smoking leads to the development of specific anti-thyroid antibodies which increases the risk of 
Hashimoto’s hypothyroidism and obviously decreases the development of Grave’s hyperthyroidism.  
Despite this, the day will never come when a physician advocates smoking for hyperthyroid patients due 
to the greater health risks associated with the behavior. 
Human Development 
 Iodine Dependency and Thyroid Hormone Synthesis 
 As examined in the introduction, iodine availability has a high degree of importance for the 
thyroid cells in manufacturing T3 and T4.  Thyroid hormone synthesis begins with the thyroid glandular 
cells and follicles sequestering iodide (the ion form of iodine) from the blood utilizing a system of iodide 
pumps; this process is known as ‘iodide trapping’.  The pumping action creates a very steep iodide 
gradient between the thyroid gland and the blood with the intrathyroidal spaces having 30 to 250 times 
more iodide ions2.  The relative concentration of iodide ions within the thyroid is hormonally dependent 
upon TSH from the anterior pituitary gland in a direct relationship.  The follicles within the thyroid are 
biologically important for reaction and storage as the endoplasmic reticulum and Golgi apparatus of the 
glandular cells coordinate to synthesize and secrete into the follicles a very large (660 kDa) glycoprotein 
molecule called thyroglobulin.  The uniqueness of this giant molecule lies in its approximately 70 
tyrosine amino acids which are used to react with the iodine to form the thyroid hormones – the 
thyroglobulin molecular literally forms a pocketed environment for the thyroid hormones to be 
synthesized within it3.  Once the thyroid hormones are produced, they remain bound to the glycoprotein to 
be stored within the thyroid.   
 The first essential step in the formation of the thyroid hormones is conversion of the iodide ions 
to an oxidized form of iodine, either nascent iodine (I0) or I3-.  This is facilitated by peroxidase located in 
the apical membrane of the cell or attached to it to so that it is in close proximity to the thyroglobulin 
molecules produced from the Golgi apparatus and the oxidized iodine is then capable of combining 
directly with the amino acid tyrosine on the glycoprotein through a process called organification2.  This 
process is enzymatically sped up via the catalytic activity of iodinase causing the process to proceed 
towards combined iodine and tyrosine in just a matter of seconds.  Tyrosine is first iodized to 
monoiodotyrosine and then to diiodotyrosine.  Then, during the next few minutes, hours, and days, more 
and more of the iodotyrosine residues become chemically coupled with one another to form thyroxine 
(T4) which will remain bound to thyroglobulin2.  Triiodothyronine (T3), as its name suggests, results from 
the chemical fusion of one molecule of monoiodotyrosine to diiodotyrosine.  T3 and T4 are stored within 
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the thyroid follicles in large amounts for months at a time and can be realized as the body requires.  When 
synthesis of thyroid hormone ceases, the physiologic effects of deficiency are not observed for several 
months2 see Figures 6 and 7. 
Iodine is not naturally produced in the body and accordingly must be acquired through external 
sources, similar to essential amino acids.  Iodine deficiency is not uncommon in developing countries due 
to improper nutritional infrastructures but many public health campaigns have been organized to rectify 
this health risk. The World Health Organization (WHO) estimates that approximately 2 billion people, 
including 285 million school-age children, still have iodine deficiency, defined as a urinary iodine 
excretion of less than 100 μg per liter12 see Figure 8.  Some physicians suggest that the more iodine in 
nutrition, the better.  Dr. Robert Utiger of Department of Medicine, Brigham and Women’s Hospital in 
Boston states that because excess iodine is rapidly urinated and thyroid hormones are deiodinized, more 
than the suggested 70 µg daily intake is required13.  He continues that infants, children, and pregnant or 
lactating women need more iodine because their thyroxine (T4) production rate is relatively high.  How 
much one should exceed the daily intake is currently debated within the medical community.  
Consequently, while iodine is an important precursor substrate to thyroid hormone function, excessive 
intake of iodine in the diet has been shown to cause hypothyroidism in some cases.  Teng, et al. showed 
that among nearly 3700 Chinese patients with varying degrees of iodine intake, those with excessive 
dietary intake were shown to have elevated tendencies towards developing overt hypothyroidism due to 
autoimmune thyroiditis12.  This is most likely due to the elevated biochemical synthesis of thyroid 
hormones that exceeded an immunologically tolerable level and ultimately triggered a cell-mediated 
immune response.  Dr. Utiger maintains that “overall, the small risks of chronic iodine excess are 
outweighed by the substantial hazards of iodine deficiency, which is still widespread. All these hazards — 
pregnancy loss, goiter, and mental retardation — are prevented by an adequate iodine intake13.”  It should 
be mentioned that excessive iodine can be accidentally introduced into the diet via unintended sources in 
dietary supplements.  One studied culprit is selenium-enriched kelp which can be common in many 
supplements14.  In addition, many radioactive CT scan contrasts can also be implicated in providing 
excessive iodine to patients with the danger of inducing thyroid disorders. 
Embryonic Thyroid Development 
 The thyroid gland begins to develop during the fourth week of gestation from a gradual 
organization of endodermal cells characterized by a thickening of the basement membrane of the 
primitive pharynx2.  The ‘proto-thyroid’ grows from its posterior regions and forms a duct-like 
invagination known as the thyroglossal duct which descends through the tissue of the neck to its final 
destination in front of the trachea, where it divides into two lobes2.  By week nine of gestation, the 
follicular cells begin forming the follicles which will contain the colloid fluid by week fourteen.  
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Throughout embryonic development, the fetus is vitally dependent upon the mother’s circulating thyroid 
hormones, particularly T4, because the fetus produces insufficient T3 levels to support normal brain 
development throughout the entire pregnancy and no fetal thyroid hormone is produced until the second 
trimester15 - even then, most thyroid hormone supplied to the fetus is from the mother.  Many birth 
defects are the cause of maladjusted thyroid hormone levels in the mother either through undiscovered 
pre-existing conditions or the natural tendency for maternal thyroid hormone levels to drop during 
gestation.  Fetuses who didn’t receive adequate hormone levels at 12 weeks of gestation and on, without a 
subsequent increase, had significant delays in neurodevelopment16 when assessed at one and two years of 
age, even when the maternal serum thyrotropin (TSH) concentration had been normal. The likely 
explanation, at least according to studies in animals, is that until a point toward the end of the first 
trimester, when the hypothalamic–pituitary–thyroid axis becomes functional, the fetal brain is dependent 
on local monodeiodination of maternal T4 for conversion to T317. A relatively low serum T4
3 3 . 
 concentration 
may be associated with a normal serum thyrotropin concentration in iodine deficiency when the thyroid 
preferentially secretes T , but maternal T  cannot be used by the fetal brain during early pregnancy18
Congenital Thyroid Development 
 Because proper thyroid functioning is vitally important to human development, Dr. Anthony 
Weetman of Northern General Hospital in Sheffield, UK feels that women with Graves’ hyperthyroidism 
should avoid pregnancy until their hyperthyroidism is adequately treated, because the rate of fetal loss in 
untreated women is high. He feels that when Graves’ hyperthyroidism occurs during pregnancy, an 
antithyroid drug should be given in the lowest dose necessary to maintain the woman’s serum free 
thyroxine concentration in the upper part of the normal reference range or just above this range. 
Combination therapy with an antithyroid drug and T4 must be avoided because the dose of antithyroid 
drug needs to be higher in patients who are also receiving T4 therapy, and little of the T4 reaches the fetus, 
resulting in fetal hypothyroidism19. 
 When talking about hypothyroidism, T4 levels are recommended to be increased during 
pregnancy.  Early in pregnancy in normal women, as a consequence of the weak thyroid-stimulating 
activity of chorionic gonadotropin, serum free T4 concentrations may increase and TSH concentrations 
may fall. For reasons that are not entirely clear, free thyroid hormone concentrations then decrease as 
pregnancy progresses, necessitating the use of trimester-related reference ranges. The other important 
change in thyroid hormone regulation is the estrogen-driven increase (by 100 percent or more) in the 
concentration of thyroxine-binding globulin; the increased number of binding sites for T4 would result in 
an even more marked fall in serum free T4 concentrations during pregnancy, unless there were a 
compensatory increase in thyroidal secretion and restoration of the equilibrium between the free 
(metabolically active) hormone and bound hormone. The raised concentration of chorionic gonadotropin 
 16
may play an important role in this homeostasis. Consequently, there is little or no appropriate 
compensation for the increased availability of binding sites on thyroxine-binding globulin, which 
effectively “mops up” substantial amounts of free T420.   
In pregnant women with primary hypothyroidism, however, the thyroid cannot respond to 
stimulation adequately. Iodine deficiency is associated with thyroid deficiency in both mother and fetus, a 
situation that makes it impossible to determine whether the mental retardation of the fetus is due to 
maternal hypothyroidism or both maternal and fetal hypothyroidism. In developed countries, chronic 
autoimmune thyroiditis is the most common cause of hypothyroidism among women in their childbearing 
years. Haddow et al. found in a study published in the NEJM that antibodies responsible for 
compromising maternal thyroid function can cross the placenta and, in some instances, compromise fetal 
and neonatal thyroid function. Decreases in development can occur even when the pregnant woman’s 
hypothyroidism is mild and probably asymptomatic. The presence of high serum concentrations of 
antithyroid peroxidase antibodies in women with hypothyroidism indicates that chronic autoimmune 
thyroiditis was the most frequent cause of hypothyroidism in these women.  Treating maternal 
hypothyroidism during pregnancy appears to be beneficial for the child, even when treatment is 
inadequate as determined by measurements of TSH16.  One study by Haddow et al. found that compared 
with controls, the children of hypothyroid mothers had significantly reduced intelligence levels16.  The 
study contributed to knowledge about fetal development and thyroid disorders by showing that subclinical 
hypothyroidism in women can have long-term consequences upon the neuropsychological development in 
their offspring, and that T4 supplementation can improve the outcome, even when supplementation is 
inadequate. 
Childhood Thyroid Development 
 Cretinism is caused by extreme hypothyroidism during fetal life, infancy, or childhood.  This 
condition is characterized by a lack of body growth and by mental retardation due to a failure of the 
thyroid gland to produce adequate thyroid hormone – likely caused by genetic defect or from an iodine 
deficiency2.  Despite a lack of height growth, abnormal weight gain is usually indicative of the disease.  
Cretinism can vary in severity depending on the degree of thyroid gland failure.  The testing procedure for 
this syndrome will be examined further in Clinical Considerations.  Thyroid levels are particularly 
important for male development as a study by Wagner et al. shows that disturbance of the normal 
euthyroid state affects the morphological and functional development of the testis. The proliferation of 
immature Sertoli cells, an event that determines the extent of sperm production, was shown to be under 
the control of thyroid hormone. Furthermore, the Sertoli cell maturation process is at least in part 
regulated by T3. Similarly, thyroid hormone was shown to play a critical role in the onset of Leydig cell 
differentiation in postnatal testis as well as in maintaining steroidogenic function with advancement of 
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age. Thyroid hormone is also likely to contribute to normal spermatogenesis and metabolic processes in 
the adult testis21. 
Adulthood Thyroid Development 
 Because thyroid disorders are most prevalent among older patients, the aging process is a major 
factor in hyperthyroidism and hypothyroidism.  Hypothyroidism is more common in people over age 60 
than hyperthyroidism as the aging process diminishes the thyroid metabolic efficacy and accordingly the 
risk of hypothyroidism increases steadily with age, with women being at higher risk.  Researchers do not 
fully understand why women are more likely than men to have thyroid problems, but it may be linked to 
estrogen. Some evidence suggests that this hormone affects the immune system, particularly the white 
blood cells called B cells that produce antibodies. This may have implications for the development of 
autoimmune diseases, like Hashimoto’s thyroiditis1.  Estrogen is also linked to thyroid diseases in 
younger women of childbearing age.  During pregnancy, due to high levels of estrogen throughout the 
body, B and T cells which act in tandem to produce antibodies are suppressed; following pregnancy as 
estrogen levels decrease normally, these B and T cells become highly active again and can lead to 
autoimmune antibody production that may lead to postpartum thyroiditis leading to hypothyroidism or 
potentially Graves’ disease depending upon the target of the antibodies as discussed earlier in this section.  
As one gets older, the body’s normal functions do not work as efficiently as they once did which is just as 
true of thyroid functioning as with the rest of the body, and accordingly thyroid malfunction can develop.   
 Acquired Thyroid Disorders 
 As was mentioned in the proceeding sections on hyperthyroidism and hypothyroidism, adult 
acquired thyroid disorders are usually the result of an existing thyroid disorder that has been 
overcompensated or the thyroid fails do to toxic levels of radiation or drugs in treating cancer or abnormal 
amounts of iodine.  Any outside influence that can affect the thyroid’s proper functioning can be thought 
of as ‘acquired thyroid disorders’.   
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III. Molecular Analysis 
Hormonal Analysis 
 Hormones Produced by the Thyroid 
 As mentioned throughout this paper, the star of the thyroid show, if you will, is triiodothyronine 
and thyroxine, better known as T3 and T4, respectively.  The IUPAC nomenclature for T3 is L-3,5,3'-
triiodothyronine and for T4 is L-3,5,3',5'-tetraiodothyronine.  These thyroid hormones are thought to be 
the only iodine-containing hormones within vertebrates22.  T3, as its name suggests, contains three iodine 
atoms while T4 contains four iodine ions.  In the process of distribution throughout the body, T4 has an 
iodine atom cleaved off so as to function as its more potent, three-iodide, counterpart.  The more active 
form of thyroid hormone, triiodothyronine (T3), is produced by deiodination of thyroxine (T4) by the 
enzymes T4 5'-deiodinase (5'-D) types I and II. Type I T4 5'-deiodinase is found predominantly in the liver 
and kidneys in which it acts to produce two thirds of the total T3 in the body. Type II T4 5'-deiodinase is 
responsible for most of the T3 found in the pituitary, the brain, and brown fat23.  Both T3 and T4 are 
characterized as tyrosine derivatives – both exhibit the basic tyrosine functionality and structure with an 
additional aromatic ring and hydroxyl group added via an ether bond see Figures 9 and 10.  These two 
figures also demonstrate the placement of the iodine ions.  As stated earlier, these hormones will bind to 
blood plasma proteins for systemic transportation due to their poor water solubility.  Once released from 
these proteins, they engage every cell in the body so as to regulate metabolism and other homeostatic 
pathways.  Although it was originally believed that thyroid hormones enter the cells by passive diffusion, 
new studies suggest that cellular uptake is facilitated by carrier-mediated processes. Several inorganic 
anion transporters and L-type amino acid transporters have been shown to facilitate plasma membrane 
transport of thyroid hormone22. 
Cellular Receptors of Thyroid Hormones 
 Genes, Functional Domains, and Receptors 
 Once inside the cell, thyroid hormones seek out thyroid hormone receptors (TRs) which mediate 
their biological activity24.  TRs belong to the superfamily of receptors known as nuclear receptors. Within 
the intracellular space, TRs form heterodimers with the retinoid receptor and act as ligand-inducible 
transcription factors. TRs have a ligand-binding domain (which binds the thyroid hormone), a DNA 
binding domain, and an amino terminal domain which all function cooperatively to regulate gene 
expression through interactions with DNA response elements and with various nuclear co-activators and 
co-repressors see Figure 11. The thyroid hormone receptors are derived from two separate genes, α and β, 
located on chromosomes 17 and 3, respectively25, leading to distinct gene products indicative of multiple 
forms of receptors through differential RNA processing. The major thyroid receptor isoforms are α1, α2, 
β1, and β2; among these, thyroid hormone receptors α1, β1, and β2 bind thyroid hormone26 (α2 is unable 
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to bind T3) see Figure 12.  For the protein receptor product, the N-terminus end interacts with 
transcription factors while the C-terminus end of the receptor interacts with the thyroid hormone ligand 
and is capable of dimerization.   
It has been shown that the thyroid hormone receptor subtypes can differ in their contribution to 
particular biological responses. Almost all tissues express the α1, α2, and β1 isoforms, but β2 is 
synthesized almost exclusively in the hypothalamus, anterior pituitary, and developing ear.   Receptor α1 
is the first isoform expressed in the developing fetus, and there is a profound increase in expression of β 
receptors in the brain shortly after birth; the β receptor preferentially activates expression of several genes 
known to be important in brain development (e.g. myelin basic protein), and upregulation of this 
particular receptor highlights the well-known effects of thyroid hormones on development of the fetal and 
neonatal brain27. Recent studies suggest that TRβ1 plays an important role in regulating TRH which 
regulates thyroid hormone actions in the liver, and regulating heart rate28 whereas TRβ2 plays an 
important role in the regulation of TSH29.   
Thyroid status influences the expression of T3-receptor mRNA and tissue T3-receptor 
concentrations. In rats, injection of T3 increases the concentration of T3-receptor-β1 mRNA and decreases 
the concentration of T3-receptor-β2 mRNA in the pituitary and the concentrations of T3-receptor-α1 and 
T3-receptor-α2 mRNA in the heart, kidneys, and pituitary30.  In humans with chronic illness, reduced 
serum thyroid hormone concentrations are associated with an increase in the expression of T3-receptor 
mRNA in peripheral-blood cells and liver-biopsy specimens31. Although it is possible that the expression 
of T3-receptor mRNA increases to compensate for low serum thyroid hormone concentrations, 
unoccupied T3 receptors repress some genes that are usually stimulated by T332. Therefore, an increase in 
T3 receptors in compensation for low serum thyroid hormone concentrations could have the opposite 
effect, reducing gene expression, depending on the gene and tissue studied. 
  
 
Interaction of Receptors with DNA 
Thyroid hormone receptors bind to short, repeated sequences of DNA called thyroid or T3 
response elements (TREs), a type of hormone response element. A TRE is composed of two AGGTCA 
‘half sites’ separated by four nucleotides. The half sites of a TRE can be arranged as direct repeats, 
palindromes or inverted repeats33. The DNA-binding domain of the receptor contains two sets of four 
cysteine residues, and each set chelates a zinc ion, forming loops known as zinc fingers. A part of the first 
zinc finger interacts directly with nucleotides in the major groove of TRE DNA, while residues in the 
second finger interact with nucleotides in the minor groove of the TRE. Thus, the zinc fingers mediate 
specificity in binding to TREs33.  Thyroid hormone receptors can bind to a TRE as monomers, as 
homodimers, or as heterodimers with the retinoid X receptor (RXR). The heterodimer affords the highest 
affinity binding, and is thought to represent the major functional form of the receptor27.  
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Nuclear Hormone Activated Transcription Factors 
 The TRs remain bound to the TRE elements regardless of whether there is bound thyroid 
hormone.  If there is no hormone bound, the TRE is inactivated and there is no gene transcription.  In the 
T3-free state, the transactivation domain of the T3-free receptor, as a heterodimer with RXR, assumes a 
conformation that promotes interaction with a group of transcriptional corepressor molecules. A part of 
this corepressor complex has histone deacetylase activity (HDA), which is associated with formation of a 
heterchromatin27 and the genes are effectively silenced. The net effect of recruiting these types of 
transcription factors is to repress transcription from affected genes. Conversely, if T3 binds to the TR, and 
accordingly the TRE complex site, this activates transcription and activation of the associated set of 
genes.  Binding of T3 to its receptor alters the conformation of the thyroid hormone receptor in such a way 
as to release the corepressor complex and recruit a coactivator complex that includes multiple histone 
acetyltransferases, including a steroid receptor family coactivator, p300/CREB-binding protein–
associated factor (PCAF), and CREB binding protein (CBP)34.  The coactivator complex contains histone 
transacetylase (HAT) activity, which imposes an open configuration on adjacent chromatin; the 
coactivator complex associated with the T3-bound receptor functions to activate transcription from linked 
genes27 see Figure 13.  Overall, the liganded structure is more compact and stable than the unliganded 
structure, at least in part because the receptor folds around the ligand. The ligand becomes buried within 
the interior of the receptor and makes multiple contacts with several helices and β-strands to stabilize the 
conformation. This arrangement suggests that the ligand plays a structural role in triggering completion of 
the receptor fold. Likewise, the several hydrophobic cavities in unliganded RXR structures indicate that 
the fold cannot be completed without the ligand35.   
The Interplay of TRH, TSH, T3, and T4 and Receptor Disorders 
The best studied examples of genes negatively regulated by T3 are the genes for the subunits of 
TSH35. The close inverse relation between serum T4 and TSH concentrations is well-known, and 
measurement of serum TSH is the single best test of thyroid function23. TSH is a heterodimer composed of 
an α subunit, common to all three pituitary glycoprotein hormones, and a specific β subunit; T3 regulates 
the transcription of the genes for both subunits35. In negative regulation, both the position and the 
sequence of the DNA-response elements differ from those that confer a positive T3 response35. In addition, 
a T3-receptor monomer rather than the usual functional dimer may confer negative regulation. The β-
subunit gene is stimulated by TRH, and the regions that confer this regulation are distinct from those that 
confer T3-receptor-mediated inhibition36. 
In regards to clinical manifestations of defective TRs, the syndrome of resistance to thyroid 
hormone is characterized by diffuse goiter, varying manifestations of hypothyroidism, elevated serum 
concentrations of T3 and T4, and normal (or elevated) serum TSH concentrations37. Specifically, 
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resistance to thyroid hormone is associated with abnormalities in the T3-receptor- β gene37. More than 20 
mutations have been identified, all contained in the terminal two exons of the gene that encode the 
hormone-binding domain causing a reduction in T3 binding. In most pedigrees, resistance to thyroid 
hormone is inherited as a dominant trait. Interestingly, a mutation in the ligand-binding domain of the 
receptor can lead to the production of a receptor that is not only inactive, but also has a dominant negative 
influence over the wild-type receptor in the case of heterozygosity32.   A mutant receptor might be able to 
interfere with the action of T3 by competing directly with the wild-type receptor for the T3-response 
element of the DNA or by inactivating the wild-type receptor by dimerization or competition for some 
limiting cofactor38. For some of the mutations associated with T3-receptor-β, this interference can be 
overcome by high concentrations of T3. This finding indicates that the serum thyroid hormone 
concentrations of a patient with resistance to thyroid hormone should be inversely correlated with the 
affinity of the mutant receptor for T338; a correlation between serum hormone concentrations and a 
specific T3
 
-receptor mutation, however, has not been consistently observed in studies 38. Clinically, 
attention-deficit disorder is found in as many as 60 percent of affected children with defective TRs . 
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The response of patients with resistance to thyroid hormone that are treated with T3 or T4 differs 
according to the tissue studied and the dose of hormone38. An important clinical question has been 
whether a specific T3-receptor mutation determines the degree of tissue resistance and response to T3 or T4 
therapy. In vitro, there are variations in the ability of high concentrations of T3 to overcome the inhibition 
of T3-response elements of specific genes caused by mutant receptors40. In vivo, the difference in tissue 
response among patients with resistance to thyroid hormone that are treated with T3 or T4 may be a 
function of the sensitivity of the response element  in the regulated gene to T3 stimulation. In addition, the 
expression of the T3-receptor-β mutant-allele mRNA may vary according to the type of tissue and even the 
phase of development. The further correlation of mutations with phenotypes will require a greater 
understanding of tissue-specific expression of mutant and wild-type alleles and receptor-type regulation of 
specific genes32.   
Specifically relating to hyperthyroidism and receptor defects, Brokken et al. have discovered that 
in hyperthyroidism, it is the TSH receptor itself that can be mutated so as to bring about the described 
symptoms of the disease.  As a side note, it has been found that TSH secretion is affected little by 
moderate doses of thyroid hormone, but high doses cause dose-dependent suppression38. Abnormal serum 
TSH concentrations, especially low serum TSH, may reflect a variety of causes, including therapy with 
drugs such as glucocorticoids and dopamine, as well as non-thyroidal illnesses41.  Antithyroid treatment 
for Graves’ hyperthyroidism restores euthyroidism clinically within 1–2 months, but physicians attest that 
it is well-known that TSH levels can remain suppressed for many months despite normal free T3 and T4 
levels42. They attribute this to a delayed recovery of the pituitary-thyroid axis. In their work, they showed 
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that the pituitary contains a TSH receptor through which TSH secretion may be down-regulated via a 
paracrine feedback loop. In Graves’ disease, TSH receptor auto-antibodies may also bind this pituitary 
receptor, thus causing continued TSH suppression42. 
There has also been development in the understanding of surface TR in regards to 
hypothyroidism.  The identification of monocarboxylate transporter 8 (MCT8), the most specific and 
powerful T3 transporter found to date43, has emphasized a significant role for membrane transporters in 
the regulation of local T3 action. The MCT8 gene on the X chromosome encodes a 613 amino acid 
protein with 12 predicted transmembrane domains. Different novel mutations in the MCT8 gene have 
been described in association with a new syndrome of X-linked mental retardation found so far in male 
infants from more than six different families worldwide44,45.   In the studies, the young males 
demonstrated global neurological defects and elevated circulating T3 levels without any of the skeletal 
and bowel manifestations associated with hypothyroidism, which suggests a specific role for MCT8 in 
CNS development. MCT8 protein has been detected in adult rat brain and a neuronal localization in 
developing rat CNS has been postulated45. However, the precise anatomical and temporal expression of 
MCT8 during brain development has yet to be described in rodents or humans. 
Non-Receptor Molecular and Genetic Defects Leading to Thyroid Disorders 
 Hyperthyroidism 
 As stated in previous sections, Graves’ disease is the leading cause of hyperthyroidism due to the 
overstimulation of the thyroid in producing thyroid hormones.  This effect has been linked to an 
autoimmune attack upon thyroid cells by self-reactive T-cells of the immune system.  It has been recently 
demonstrated by Sharpe and Abbas that CTLA-4 polymorphisms in humans have been linked to 
susceptibility to autoimmune diseases, including type-1 diabetes and autoimmune thyroid disease, namely 
Graves’ and potentially Hashimoto’s Disease46.  Sharpe and Abbas state that cytotoxic T-lymphocyte–
associated antigen 4 (CTLA-4) is a CD28 homolog that also binds to B7-1 and B7-2 but is expressed in 
an inducible fashion after T-cell activation. Unlike CD28, CTLA-4 shuts off T-cell responses by 
inhibiting interleukin-2 production and blocking cell-cycle progression.  Thus, CTLA-4 is involved in the 
induction and maintenance of T-cell tolerance.  A study by Marazuela et al. corroborates the malfunction 
of CTLA-4 by finding that T regulatory cells are abundant in inflamed thyroid tissue but are unable, in 
most cases, to down-regulate the autoimmune response and the tissue damage seen in auto-immune 
thyroid disease47.  In further study by researchers at UCLA48, scientists and physicians have discovered 
the specific antibody that fails to recognize patients’ thyroid gland as self and mistakenly mounts an 
attack against the organ.  Consistent with Graves’ ophthalmopathy, the thyroid then goes into overdrive, 
producing excess levels of hormone that can cause inflammation and damage to the body and attack the 
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tissue behind the eyes, causing them to protrude. In extreme cases, patients experience trouble closing 
their eyelids, severe double vision, corneal scarring, optic nerve damage and even blindness.   
In the study, UCLA researchers discovered that T-cells taken from patients with Graves' disease contain 
an abnormal surplus of the receptor targeted by this antibody and the new antibody binds to the excess 
receptors on the T-cells, mimicking the actions of a hormone called IGF-1, or insulin-like growth factor 1. 
Similar to insulin, IGF-1 stimulates cell growth while suppressing normal cell death. The team suspects 
that this mechanism prolongs the survival of older T-cells, causing a cascade of autoimmune problems 
that spur the body to attack its own tissue. 
 Hypothyroidism 
 Moreno et al. at Erasmus Medical Center, in Rotterdam, Netherlands have discovered a genetic 
defect in thyroid hormone synthesis that has been linked to hypothyroidism.  DEHAL1 has been identified 
as the gene encoding iodotyrosine deiodinase in the thyroid, where it controls the reuse of iodide for 
thyroid hormone synthesis49, as discussed in Human Development.  Moreno and his colleagues studied 
patients who had been clinically diagnosed with hypothyroidism and presented with features suggestive 
of an iodotyrosine deiodinase defect for mutations in DEHAL1. The patients who were discovered to have 
this genetic defect had a dramatic reduction of in vitro activity of iodotyrosine deiodinase. Accordingly, 
because of the reduction in the enzyme’s activity, insufficient amounts of T3 or T4 were produced.  
Consistent with normal hypothyroid symptoms, their studied patients had severe goitrous hypothyroidism, 
which was evident in infancy and childhood. Two of their patients also had cognitive deficits due to late 
diagnosis and treatment. Moreno’s study suggests that because infants with DEHAL1 defects may have 
normal thyroid function at birth, they may be missed by neonatal screening programs for congenital 
hypothyroidism. 
 Thyroid Cancer 
 Identified by Sidransky, et al., the BRAF gene has been found to be activated by mutation in 
human cancers, predominantly in malignant melanoma50. They tested 476 primary tumors, including 214 
lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers for the BRAF 
T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 
24 of the 35 papillary thyroid carcinomas examined, they found a missense T to A transversion at 
nucleotide 1796 in the BRAF gene, hence the label ‘T1796A’. The T1796A mutation was detected in four 
lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Their data 
suggests that activating BRAF mutations may be an important event in the development of papillary 
thyroid cancer. As a means of histological reference, papillary and follicular thyroid carcinomas originate 
from thyroid follicular epithelial cells.  Papillary thyroid cancer (PTC) is the most common thyroid 
cancer, accounting for about 80 percent of thyroid malignancies51. Sidransky and his team assert that 
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determination of the presence or absence of the transversion in a sample can be used to provide a 
diagnosis, to decide whether to perform surgery, and to decide what drugs or radiation will be used; drugs 
which may be prescribed include chemotherapeutic agents, therapeutic antibodies, therapeutic anti-sense 
oligonucleotides or constructions, or small interference RNAs (iRNAs). They suggest that thyroid cancers 
can be treated using any agent which will inhibit BRAF expression or activity, or an inhibitor of the Ras-
Raf-MAPK or Raf/MEK/ERK pathways.  A prognosis may constitute an estimated life expectancy, a 
prediction of recurrence, or a recommendation for an aggressive or non-aggressive therapeutic regimen. 
Although PTC is usually indolent and curable with surgical thyroidectomy followed by radioiodine 
treatment, many patients do have recurrence and some become incurable and die50.   
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IV. Clinical Considerations – Testing, Pharmacology, and Systemic Integration 
Testing 
Despite the various complexities related to thyroid disorders, it should be noted that the most 
controversial areas of thyroid studies have been in determining the recommended ranges for proper TRH, 
TSH, and thyroid-produced hormone levels.  While this section will attempt to present the most recent 
information regarding the recommended serum test guidelines, it is very likely the reader could find 
slightly different values in other texts.  However, because of the ubiquitous importance of proper thyroid 
functioning, most physicians will agree on the need for prudent thyroid hormone testing and careful 
thyroid disorder diagnosis.  The American Thyroid Association (ATA) recommends that all adults be 
screened for thyroid problems with a TSH blood test beginning at age 35 and every five years thereafter1.  
Of course, the reader certainly should appreciate the relevance of thyroid functioning at all ages and 
physicians should be diligent to monitor patients for thyroid functioning throughout their lifetime.  The 
Harvard Medical School’s Health Report, Thyroid Disease, presents the various thyroid diseases in a very 
clear manner, and the subsequent section will rely on its clarity and thoroughness of the material.   
 Hyperthyroidism 
In diagnosing patients for hyperthyroidism, the first step for physicians is recognizing the 
possibility for disease manifestation by identifying hyperthyroid symptoms as listed in previous sections 
of this review.  Blood testing for hyperthyroidism and hypothyroidism involve the same tests used to 
check hormone levels with some additional tests being common for hyperthyroid patients.   
The first test in diagnosing hyperthyroidism is evaluating serum TSH level. The TSH test is the single 
best screening test to determine thyroid disease1 assuming that the patient does not have an unusual 
disorder of the pituitary gland that interferes with the normal production of TSH (for instance, elevated 
TSH serum levels could be linked to a TSH-secreting pituitary tumor); if this test comes back normal, that 
means the levels of TSH circulating in the bloodstream are within normal ranges and the patient is 
considered euthyroid. The normal range of TSH in the bloodstream is between 0.45 and 4.5 milli-
international units per liter (mIU/L), according to a report by a large panel of endocrinologists published 
in the Journal of the American Medical Association in 2004. If the TSH test is abnormally low, the 
patient will have a free T4 test or a series of tests that estimate free T4. If the free T4 levels are elevated, 
the patient is diagnosed as having a hyperthyroid1.  Before being converted from T4, most of the T3 
hormone circulating in the bloodstream is bound to plasma proteins. Accordingly, in diagnosing 
hyperthyroidism, tests to measure T3 are similarly utilized.  A total T3 test measures the total amount of 
circulating T3, and a free T3 test measures T3 that is freely circulating and available for use by the body. 
Another way to calculate the amount of free T3 is to estimate the free T3 index; this calculation combines 
the results of a total T3 test with a T3 resin uptake test, which measures the binding protein sites in the 
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blood1. The T3 index is preferred because it is considered more precise and reliable than the free T3 test.  
The normal free T3 range is 230 – 619 pg/dL52. T3 tests are not typically used in the diagnosis of 
hypothyroidism because, in people with an underactive thyroid, T3 levels are the last to fall1. Further, 
patients can be severely hypothyroidic and have a normal T3. However, T3 levels can sometimes help 
doctors diagnose hyperthyroidism or determine how severe hyperthyroidism is as free T3 level is likely to 
be elevated; even if the TSH test comes back low and the free T4 test comes back normal, and only the 
free T3 index is elevated, hyperthyroidism is indicated1.  In addition to testing for thyroid hormone levels, 
another way of confirming hyperthyroidism is to perform a thyroid antibody test.  The presence of TRAb 
antibodies that work against the TSH receptor on the thyroid gland, including thyroid-stimulating 
immunoglobulin (TSI), confirm the presence of Graves’ disease1.  Beyond the thyroid antibody tests, 
many radioactive testing procedures are utilized.  A radioactive iodine uptake (RAIU) test measures how 
much iodine the thyroid gland is able to collect. For this test, one swallows a pill containing radioactive 
iodine a day a before the test then a probe measures the radioactive signal given off from the neck in the 
area of the thyroid1.  If the thyroid has taken up an unusual amount of iodine, the patient is likely 
hyperthyroidic.  Finally, a radioactive thyroid scan images the thyroid utilizing an intravenously 
introduced radioactive indicator and a specialized camera.  Thyroid abnormalities can be determined by 
the size of the thyroid; accordingly, an abnormally large thyroid may be indicative of hyperthyroidism. 
 Subclinical Hyperthyroidism 
Because there isn’t a clear dichotomy between ‘euthyroid’ and ‘hyperthyroidism’, a spectrum 
necessarily exists and there is accordingly a condition called subclinical hyperthyroidism where 
hyperthyroid symptoms exist but hormone levels are in the ‘normal ranges’.   The combination of an 
undetectable serum TSH concentration, as measured by an assay with a threshold of detection that is 0.1 
mU per liter or less, and normal serum T3 and T4 concentrations (usually at the upper end of the normal 
range), is characteristic of subclinical hyperthyroidism1. This condition reflects the fact that before 
clinical features of thyrotoxicosis (elevated thyroid hormone levels) are apparent, the thyrotrophs in the 
anterior pituitary responsible for secreting TSH2 usually respond to minor incremental change in thyroid 
hormone concentrations, which remain within the normal range, by switching off the production and 
secretion of TSH53. Subclinical hyperthyroidism is classified as ‘endogenous’ in patients with thyroid 
hormone production associated with nodular thyroid disease or underlying Graves’ disease; it is classified 
as ‘exogenous’ in those with undetectable serum TSH concentrations as a result of treatment with 
levothyroxine (synthetic T4) 53. This paper will discuss treatments for thyroid disorders later in this 
section. 
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Hypothyroidism 
 In diagnosing hypothyroidism, a physician would go about examining the patient in much the 
same way as if hyperthyroidism was expected.  The physician would look for the characteristic signs of 
hypothyroidism and if they were present, the patient would receive many of the same tests already 
described, but their serum hormone levels would likely fall within the hypothyroid ranges. 
The first indicator of hypothyroidism is a high TSH level meaning that the pituitary gland is signaling for 
the thyroid to produce elevated levels of T3 and T4 because the serum levels of those hormones are 
abnormally low.  As a side note, in my personal experience of being diagnosed with hypothyroidism, my 
serum TSH was slightly over 14 mIU/L while the upper limit of the normal range is given to be 4.5 
mIU/L.  Needless to say, my body was screaming for more thyroid output.  In addition to TSH, T4 levels 
can also be analyzed.   Once secreted by the thyroid, most T4 is bound to serum proteins and not readily 
available for use by systemic cells. Despite this, a very small percentage of all the circulating T4 is not 
bound to proteins—that is, it is ‘free’ and available for immediate use by systemic cells. Enough free T4 
must be present to keep up with the demands of cells; bound T4 acts as a circulating reservoir that is 
continually replenished by the thyroid in equilibrium with the amount of free T4 used by the cells1 - this 
‘free’ amount is what is tested for diagnostic purposes. The normal range of free T4 is 0.8–2.0 nanograms 
per deciliter (ng/dL), according to a 2004 consensus panel recommendation1. In combination, the TSH 
test and the free T4 test give a precise account of how the thyroid gland is functioning.   Elevated TSH 
levels and low free T4 are characterized as primary hypothyroidism meaning that the disorder lies in the 
thyroid because the thyroid is not integrating the TSH signal properly; conversely, low TSH and low free 
T4 indicates that the disorder is the cause of a malfunctioning pituitary gland or hypothalamus because 
there is insufficient thyroid stimulation and is conventionally called secondary hypothyroidism.  Antibody 
tests also exist for hypothyroid diagnosis.  Testing for the presence of anti-Tg and anti-TPO antibodies 
would indicate that a patient has Hashimoto’s thyroiditis.  In addition, this test may help determine 
whether a patient with subclinical hypothyroidism is at risk for developing hypothyroidism1.  
Subclinical Hypothyroidism  
As with hyperthyroidism, there exists a subset of patients who can be identified as having 
subclinical hypothyroidism.  This ‘disorder’ is characterized by high levels of TSH and normal free T4 
levels which may or may not cause symptoms1. There is considerable, on-going debate over whether 
subclinical hypothyroidism should be treated or not.  Surks et al. concluded after doing a study on 
subclinical hypothyroidism that associations of subclinical thyroid disease with symptoms or adverse 
clinical effects are few. They felt that the consequences of subclinical thyroid disease (serum TSH 0.1-
0.45 mIU/L or 4.5-10.0 mIU/L) were minimal and recommended against routine treatment of patients 
with TSH levels in these ranges54.  However, there is a sizeable portion of physicians who would 
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advocate for the treatment of subclinical hypothyroidism due to the harmful effects a slightly underactive 
thyroid can engender.   
Pharmacology 
 Hyperthyroidism 
 In treating hyperthyroidism, there are three main classes of treatments that are widely accepted as 
being effective.  The three types of treatment for hyperthyroid patients are radioactive iodine treatment to 
destroy part of the thyroid, medications that block the thyroid’s ability to produce hormones, and simply 
removing all or part of the thyroid via surgical procedures.  
The administration of radioactive iodine, a procedure sometimes called radioiodine ablation, is 
known to be a safe and effective way to offset hyperthyroidism and is the most widely used treatment for 
hyperthyroidism in the United States1. Radioactive iodine (I131) that is ingested as liquid or in pill form, 
destroys a significant portion of the thyroid due to localized radiation poisoning and because there is a 
decrease in thyroid tissue, there is a reduction in the production of thyroid hormone to euthyroid levels. 
Most of the time this process destroys the thyroid to a point where the patient becomes hypothyroid, and 
then the patient is easily treated with synthetic thyroid hormone for the rest of their life.  The typical dose 
of radioactive iodine typically ranges from 5 to 30 millicuries (mCi) while a larger dose, between 30 and 
75 mCi, may be used to shrink larger thyroid glands that are causing problems with breathing1. Because 
of the inherent risks in radioactive treatments, some experience radiation-induced inflammation causing 
hyperthyroidism to worsen temporarily, sometimes accompanied by neck pain (yet this can be acutely 
treated) and for others with Graves’ disease their eye problems worsen after radioactive iodine; those at 
highest risk for these side effects are smokers with severe, unstable eye disease whose thyroid levels are 
not well regulated after receiving radioactive iodine1. 
As the second class of treatment options, antithyroid drugs – either methimazole (Tapazole®) or 
propylthiouracil – block the thyroid gland’s ability to make hormone and therefore reduce the level of 
thyroid hormone distributed throughout the body.  The advantage of antithyroid drugs is that they do not 
leave the thyroid permanently damaged. The downside is that there is some uncertainty as to how long the 
patient is required to take them, and they can have serious side effects. Using antithyroid drugs for about a 
year or two may cause hyperthyroidism to go into a prolonged state of remission but in a sizeable portion 
of patients there is a marked incidence of relapse1.  If the treatment does not produce results, radioactive 
iodine therapy may be used because it has minimal risks and a much better success rate, albeit there is 
destruction of the thyroid. A potential risk of antithyroid drugs is that they can lower the patient’s white 
blood cell count making them more susceptible to infection1.  
 Finally, the third class of hyperthyroid treatment is surgery.  Having all or part of the thyroid 
gland removed is called thyroidectomy. However, with the success of radioactive iodine therapy, this 
 29
surgery is typically reserved for patients with very large goiters or nodules that are causing breathing or 
swallowing difficulties1. Surgery is also useful for people who may be resistant to radioactive iodine 
treatment. Surgery may also be a good choice for pregnant women whose conditions cannot be controlled 
with conservative doses of antithyroid drugs and for patients who are allergic to antithyroid medications. 
 Hypothyroidism 
For patients with hypothyroidism, the aim of treatment is to artificially supplement the levels of 
thyroid hormone which are below normal ranges via thyroid hormone replacement to closely replicate 
normal thyroid functioning. Pure synthetic T4, called levothyroxine sodium, works in the same way 
natural thyroid hormone works. Normally, a single dose taken consistently every day on an empty 
stomach, when properly titrated, resolves hypothyroid symptoms and restores normal hormone levels; for 
patients who have developed a goiter because of Hashimoto’s thyroiditis, treatment with synthetic thyroid 
hormone may help shrink the goiter or prevent it from growing.  The dose of levothyroxine is determined 
by weight, age, any other medical conditions, and the severity of hypothyroidism. A general guideline is 
0.8 mcg for every pound of weight (or 1.6 mcg for every kilogram of weight)1.  Levothyroxine sodium is 
available in a wide range of strengths, from 25 mcg to 300 mcg.  Someone with autoimmune-induced 
hypothyroidism may require only partial hormone replacement because the thyroid is still producing some 
hormone whereas a person whose thyroid has been removed requires total hormone replacement1.  
Because T4 is a slow-acting hormone, its affects may be not be seen immediately and usually take 
between six and eight weeks after initiation of treatment.   Because of the need to start off hormone 
replacement therapy slowly, and the long time of action, multiple TSH and free hormone tests are usually 
recommended to properly establish the dosage. 
It is general consensus among healthcare providers that there is little difference in effectiveness 
among brand name T4 replacement medications1. Some of the major brand names of synthetic T4 are 
Synthroid®, Levothroid®, Levoxyl®, and Levo-T®.  However, problems with thyroid drugs can occur 
when a patient switches brands. The reason for this is that each brand is manufactured in slightly different 
processes than the others. For instance, they all have the same active ingredient, levothyroxine sodium, 
but the inactive ingredients may vary1. These small differences can have a significant impact on the 
drug’s bioavailability— that is, how much T4 the body absorbs.  Beyond utilizing brand name 
medications, using generic versions of levothyroxine sodium is risky because generic products are often 
interchanged for one another and the dosage of hormone that the patient receives may be variable thereby 
fluctuating TSH and T4 levels – even slight changes in amounts of T4 absorbed may affect overall health. 
New generic drug formulations regularly become available in the marketplace despite a strong position 
taken by three professional associations of endocrinologists and thyroidologists stating that FDA testing 
methods used to ensure bioequivalence among products are flawed1.  From personal experience, my 
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personal physician highly recommends against taking the generic thyroid product due to habitual 
ineffectiveness. 
It is also important to note that certain drugs, such as iron or calcium supplements, antacids, and 
cholesterol-lowering medications, can interfere with the absorption of T41.  One such study confirmed that 
malabsorption of T4 has been described in patients treated with drugs that modify an acidic 
environment55.  They found that the daily requirement of T4 was higher (by 22 to 34 percent) in patients 
with H. pylori–related gastritis, atrophic gastritis, or both conditions than in the reference group.  They 
concluded that patients with impaired acid secretion require an increased dose of T4, suggesting that 
normal gastric acid secretion is necessary for effective absorption of oral T4.  Certain medications can 
induce thyroid disease.   A possible drug interaction that affects the body’s usage of thyroid hormone is 
the tuberculosis drug, rifampin.  Takasu and his colleagues found in a study that patients who were on 
rifampin, and were otherwise euthyroidic, become hypothyroidic within several weeks56. Another drug, 
lithium, a drug widely used to treat bipolar disease (also known as manic depression), interferes with the 
production of thyroid hormone and decreases the amount of hormone secreted into the bloodstream. 
Long-term treatment with lithium results in goiter in up to 50 percent of patients, subclinical 
hypothyroidism in up to 20 percent, and hypothyroidism in up to 20 percent1. 
Most patients who are diagnosed with hypothyroidism are treated with only synthetic T4.  
However, as Bunevicious et al. determined, there may be more to ameliorating symptoms of 
hypothyroidism than just providing T457.  They found that although this treatment is effective, some 
patients with hypothyroidism treated with T4 are not entirely well – referring to their mood and 
neurophysiological health.  Part of their rationale for studying a ‘mixed’ treatment was the existence of 
differences in the rate of conversion of T4 to T3 in different tissues, and thus they compared the effects of 
T4 alone with those of T4 plus T3 on thyroid hormone actions in the brain, pituitary gland, and other 
organs in patients with hypothyroidism.  They found that in patients with hypothyroidism, partial 
substitution of T3 for T4 may improve mood and neuropsychological function57.  Stated in their findings, 
they believed this difference to be caused by differential uptake of the two thyroid hormones between 
tissue types.  In addition, they believed that there study confirmed the dual secretion of T3 and T4 within 
the body as necessary for normal biological functioning.  A combination of T4 and T3 is commercially 
available under the generic name liotrix (Thyrolar®). Many physicians prescribe this because of the ‘good 
feeling’ that arises although the potency and short life of T3 limit its usefulness1. For example, liotrix 
contains a preparation of T4 and T3 in a 14:1 ratio, which is relatively more T3 than is produced naturally 
within the body. Taking liotrix produces a very high level of T3 for a short time, and then the level falls 
off very rapidly. So, soon after taking it, the body receives a surge of excess thyroid hormone that may 
cause some temporary hyperthyroid symptoms, or thyrotoxicosis1. 
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Synthetic T4 is the preferred choice among doctors because it provides stable levels of the 
hormone and is well absorbed but desiccated thyroid, made mostly from pig thyroid gland, is still 
prescribed by some doctors in the United States1. Its proponents value it as a natural alternative to more 
common levothyroxine sodium treatments and others claim that they feel better using this product than 
they do using synthetic T41.  Potency of desiccated thyroid can vary from one batch to another depending 
on several factors, including environmental influences such as the animal’s diet. Being an animal product, 
they contain hormones and proteins that don’t normally exist outside the thyroid gland. Some patients 
develop allergic reactions to the animal proteins; such reactions are far less common among people who 
use synthetic T4
.     
.  Also, animal thyroid pills are not entirely ‘natural’: they contain chemicals, called 
binders, used to make the tablets1
Thyroid Disorders and the Pharmaceutical Industry 
To digress briefly, showing preference to the United States system of approval, the Food and 
Drug Administration’s (FDA) clinical process will be examined from trial to approval in this section and 
will end with some specific mentions of where thyroid treatments fit into the multi-billion dollar 
pharmaceutical industry.   
 Clinical Trials and the Approval Process 
As just mentioned, the FDA is responsible for assuring that foods and cosmetics are safe and that 
medicines and medical devices are both safe and effective58. To carry out this responsibility, the FDA 
monitors more than $1 trillion worth of products, representing about $0.25 of every $1.00 spent annually 
by American consumers59.  Because of their vital oversight of products and responsibility to consumers, 
they have in place a very rigid system which grants products, particularly drugs, approval.  The drug 
development process is generally and conventionally divided into phases. The first step of the approval 
process is the preclinical trial which involves three to four years60 of extensive preliminary research to 
develop hypothesizes, perform biochemical analysis, and undergo experimentation both in vitro and in 
vivo in animal subjects.  Much like this paper, the early stages of drug development require a synthesis of 
scientific information as collaboration between biology, chemistry, and especially biological computer 
science are vitally necessary in today’s cutting edge pharmacological expansion.  Some of the goals of 
this early development are to make sure animal subjects are not genetically harmed or the drug doesn’t 
cause toxic damage.  If successful, this phase is followed by an application to the FDA on behalf of the 
drug in question as an investigational new drug (IND).  In the IND, the pharmaceutical firm must both 
present the discovered data and show why continued investigation in humans is necessary and possibly 
effective58.   
After an IND is approved, the next steps are clinical phases 1, 2, and 3, which require roughly six 
years for completion.  Clinical phase 1 is characterized by the drug being voluntarily utilized in healthy 
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patients to determine the pharmacologic actions, safe dosage range, and duration of a drug; this initial 
phase is important because it reveals how the drug will be absorbed, distributed, metabolized, and 
excreted58.  Following clinical phase 1, clinical phase 2 is important because this is the first step in the 
process during which the drug is administered to affected patients who have volunteered to be involved in 
the trial.  During this phase, the effectiveness and side effects caused by the drug are determined.  In 
phases 1 and 2, just enough patients are used to yield statistically reliable data without putting patients at 
an unnecessary risk.  Finally, in clinical phase 3, more affected patients volunteer to use the drug to give 
an even greater analysis of the effectiveness and also revealed long-term side effects.  Typically, clinical 
phase 2 is tested on 3 to 5 times as many patients as phase 1, while clinical phase 3 is tested on 10 times 
as many patients as phase 258.  Following these three clinical trials, the pharmaceutical manufacturer will 
file a new drug application (NDA) with the FDA for approval.  The application contains information on 
the chemical makeup and manufacturing process, pharmacology and toxicity of the compound, human 
pharmacokinetics, results of the clinical trials, and proposed labeling. An NDA can include experience 
with the medication from outside the United States as well as external studies related to the drug58.  At 
this point, the FDA may approve or reject the application under various conditions or recommendations– 
for instance, they may require more testing for the drug to be approved or post-approval testing to further 
verify the drug’s nature.  ‘Post-marketing surveillance’ is important, because even the most well-designed 
phase 3 studies might not uncover every problem that could become apparent once a product is widely 
used. Furthermore, the new product might be more widely used by groups that might not have been well 
studied in the clinical trials, such as elderly patients59.   
From the beginning preclinical trial to NDA approval, the entire process may take up to 12 
years60; because of this, the total development cost for a new drug may be more than $500 million61.  
While certainly being a long, daunting process, the success rate for final FDA approval is even more 
daunting: for approximately every 5,000 to 10,000 compounds that enter preclinical testing, only one is 
approved for marketing62.  For there to be such a plethora of thyroid disorder treatments available, it is a 
testament to modern science’s understanding of how the thyroid works and the implementation of this 
knowledge by pharmaceutical corporations that has led to so many developments. 
Thyroid Drug Companies 
As a treatment class, the drugs associated with hyperthyroid disorders have less of a commercial 
pharmaceutical history than their hypothyroid counterparts.  The radioactive iodine treatments utilized in 
the detection and treatment of some forms of hyperthyroidism are not produced on a commercial basis 
and thus this section will not discuss them any further.  Antithyroid drugs are produced on a commercial 
pharmacological basis with Tapazole® being manufactured by King Pharmaceuticals.  The generic name 
for this drug is methimazole; as mentioned earlier, this drug is classified within the ‘antithyroid’ class.  
 33
Another anti-thyroid drug, propylthiouracil (PTU) is produced as a generic brand only, much like the 
aforementioned radioactive iodine compounds.   
 Hypothyroid treatments as they are known today are actually a rather recent accomplishment.  
Although oral T4 drugs have been marketed in the United States since the 1950s, the approval of 
Unithroid® (a generic drug manufactured by Jerome Stevens Pharmaceuticals) in 2000 marked the first 
time that a single ingredient oral T4 product has been approved by the FDA63.  The unapproved thyroid 
hormone replacement products that had been on the market before 2000 were associated with instability 
of their chemical compound and inconsistent potency problems; accordingly, this led to multiple product 
recalls and risk for serious health consequences as referenced earlier in this section.  Currently, there are 
multiple pure T4 hormone replacement therapies for hypothyroid patients which have been determined to 
be safe and effective by the FDA and meet their standards for manufacturing processes, purity, potency, 
and stability.  The hormone replacement products available are Cytomel® (synthetic T3) and Levoxyl® 
(synthetic T4) manufactured by King Pharmaceuticals, Levothroid (synthetic T4) manufactured by Forest 
Pharmaceuticals, Synthroid® (synthetic T4) manufactured by Abbott Labs, and Thyrolar® (synthetic T3 
and T4) manufactured by Forest Pharmaceuticals.  As mentioned earlier, in addition to the purer synthetic 
hormone treatments, the desiccated animal thyroid products are Armour Thyroid® manufactured by Forest 
Pharmaceuticals, Bio-Throid® manufactured by BIO-TECH Pharmacal, Inc., and Naturethroid® and 
Westhroid® manufactured by Western Research Laboratories.  Finally, Thyrogen®, manufactured by 
Genzyme, is used as a thyroid hormone replacement for thyroid cancer patients undergoing testing for 
cancer recurrence who have a goiter64.  Despite the similarities among these thyroid drug products, it 
should always be stressed that the patient should read all of the accompanying drug literature thoroughly 
even after being prescribed it by a medical professional so that the desired effects have the greatest 
probability of being realized.  More information on these drugs are readily available from the Food and 
Drug Administration’s website (fda.gov).   
On an interesting side note, Synthroid® has a bit of infamy tied to it in regards to a clinical 
investigation sponsored by its pharmaceutical producer.  A 2000 NEJM article by Dr. Thomas 
Bodenheimer investigates the sometimes contentious relationship between clinical investigators and the 
pharmaceutical industry and details Synthroid®’s sponsored investigation65.  In 1987, the manufacturer of 
Synthroid® contracted with University of California researcher Betty Dong to study whether Synthroid® 
was more effective than competing thyroid preparations.  In 1990, Dong found Synthroid® to be no more 
effective than other preparations, including generic preparations. The sponsoring company refused to 
allow the findings to be published; the contract with Dong stipulated that no information could be 
released without the consent of the manufacturer. Her findings were eventually published in 1997 
following several lawsuits.  Bodenheimer states that without industry funding, important advances in 
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disease prevention and treatment would not have occurred. He quotes Lee Goldman, chairman of the 
Department of Medicine, University of California at San Francisco, that “companies translate biologic 
advances into useable products for patients. They do it for a profit motive, but they do it, and it needs to 
be done.” Undoubtedly, professionalism is held in the highest regard, but Bodenheimer adds that when 
results are disappointing for a company, conflicts may develop because of the funding being provided by 
the pharmaceutical corporation; he quotes a doctor familiar with these processes that “Companies can 
play hardball, and many investigators can’t play hardball back. You send the paper to the company for 
comments, and that’s the danger. Can you handle the changes the company wants? Will you give in a 
little, a little more, then capitulate? It’s tricky for those who need money for more studies.”  Bodenheimer 
concludes that a balance of interests and profit incentives in a competitive market is possible, but in the 
meantime the pharmaceutical industry must honor its professional code with the academic side of clinical 
trials.  It must also be weary of commercial sector drug trials because of their willingness to appease their 
source of funding which risks public distrust of the results. 
Systemic Ramifications of Abnormal Thyroid Functioning 
 Cardiovascular Health 
 Hyperthyroidism, by definition, is indicated by overproduction of thyroid hormones, commonly 
called thyrotoxicosis, which permeate throughout the body thereby abnormally ‘speeding’ up the body’s 
biological pathways.  This condition has the greatest systemic effects upon the cardiovascular system.  
Typical cardiovascular symptoms found at presentation of thyrotoxicosis include palpitation, tachycardia, 
exercise intolerance, exertional dyspnea and orthopnoea66.  While these symptoms are present in the 
majority of subjects with overt thyroid hormone excess, their clinical importance is overshadowed by the 
challenges posed by atrial fibrillation (AF), which occurs in 5 to 15 percent of patients with 
thyrotoxicosis67.  Despite this association, when subjects with new onset of AF have been investigated, 
overt hyperthyroidism has been reported to be an uncommon cause (<1%).  So although hyperthyroidism 
is a risk factor for AF, this association is uncommon in the absence of additional symptoms and signs of 
thyrotoxicosis68.  Effective treatment of thyrotoxicosis is frequently associated with restoration of sinus 
rhythm; in those with new-onset AF complicating thyrotoxicosis, spontaneous reversion to sinus rhythm 
may occur in up to 50 percent of patients, and typically does so within a few months of restoration of 
euthyroidism69. In addition to overt thyrotoxicosis, AF has been shown to be associated with subclinical 
hyperthyroidism, meaning hyperthyroidic levels that are not quite out of normal ranges, which normally 
occurs in older patients70.  Other cardiovascular conditions that have caused death in patients with 
thyrotoxicosis are cardiovascular disease, rheumatic heart disease, hypertensive heart disease, ischemic 
heart disease, and cerebrovascular disease71. 
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 Hypothyroidism also plays a role in influencing cardiovascular complications, obviously for 
opposite reasons than hyperthyroidism, but the studies confirming the connection are ambivalent at best.  
The symptoms of cardiovascular defects that are typical of hypothyroidism are opposite to those of 
thyrotoxicosis, but they are generally accompanied by fewer symptoms and signs66. Overt hypothyroidism 
has been reported to be specifically associated with cardiovascular disease, although evidence for a true 
association is largely confined to older literature reporting findings from a relatively small numbers of 
patients72; given the hypercholesterolemia and diastolic hypertension found in overt thyroid failure, such 
an association is, however, plausible.  Further, there is danger in introducing T4 replacement therapy in 
those with hypothyroidism and ischemic heart disease because of the risk of worsening angina or 
induction of myocardial infarction67.  Conversely, a study on a large series of patients treated for 
hypothyroidism and evaluated for new or worsening angina indicated an improvement in the symptoms of 
ischemic heart disease in many subjects73.  Given the likely association of untreated overt hypothyroidism 
with cardiovascular disease, much attention has focused on the possible link between subclinical 
hypothyroidism and cardiovascular disease. Again, it has been hypothesized that such a link could be 
mediated via an adverse effect of mild thyroid deficiency on the lipid profile, although the nature and 
degree of this adverse influence remain controversial and is probably relatively minor74. 
 Skeletal Health 
 Thyroid hormones are known to exert direct effects upon bone formation and mineral absorption 
so that a thyroid hormone excess results in net loss of bone and hence reduction in bone mineral density 
(BMD)75. It is well recognized that overt hyperthyroidism results in reduction in BMD and that treatment 
of the disease results in an increase in BMD. However, even with effective antithyroid therapy a complete 
restoration of BMD to pre-morbid levels does not always occur75.  Like overt hyperthyroidism, 
subclinical hyperthyroidism (especially that associated with T4 therapy) has been implicated in the 
development of osteoporosis67. Early studies reported significantly reduced bone mass in patients on 
prolonged T4 treatment76,77 resulting in concern about the potential risk of premature development of 
osteoporosis in patients receiving T4 therapy78. However, several well-conducted studies subsequently 
failed to demonstrate any detrimental effect on bone mass in T4-treated patients, even in those taking T4 in 
doses sufficient to suppress serum TSH79,80.  Overall, the data regarding clinically apparent osteoporosis 
and thyroid status support an adverse effect of overt hyperthyroidism upon fracture risk, an effect that 
may be sustained despite successful antithyroid therapy. However, there is little evidence that T4 therapy 
alone, even in doses sufficient to suppress serum TSH, is associated with increased risk of fracture, 
although caution must be exercised in high risk groups, especially postmenopausal women (and possibly 
men)67. 
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Other Organ Systems Affected 
 As stated earlier in Human Development, maternal thyroid abnormalities can have several 
debilitating effects upon the nervous and mental development of children during gestation.  Further, 
thyroid hormones also exert effects on many other organs systems including the lungs, skin, gut, kidney 
and liver mainly because of the respective ‘speeding up’ or ‘slowing down’ of metabolic functions.   
Advancing Treatments 
 Because thyroid hormones have wide-ranging effects throughout the body, namely on 
metabolism, other uses for thyroid-replacement therapies have been hypostulated, and more recently, 
studied in clinical settings. Due to the diverse receptor types which are characteristic of TRs, non-thyroid-
related uses have been suggested.  Because there is some effect of thyroid hormone on the liver, which 
regulates lipid and cholesterol profusion throughout the body, a therapeutically beneficial effect of thyroid 
hormone is the lowering of serum low density lipoprotein (LDL)81.  It has been found that 
hyperthyroidism is associated with low total serum cholesterol, which is attributed to thyroid hormone 
increasing hepatic LDL receptor expression and stimulating the metabolism of cholesterol to bile acids82.  
Hypothyroidism, in turn, has been associated with hypercholesterolemia and thyroid hormone 
replacement therapy is known to lower total cholesterol83.  Thyroid hormone has been shown in animal 
models to have the beneficial effect of increasing HDL cholesterol and improving the ratio or LDL to 
HDL by increasing the expression of apoA-1, one of the major apolipoproteins of HDL84.  The most 
prominent abnormality is a decrease in cholesterol clearance caused by a decrease in LDL receptors. The 
elevation of the serum LDL cholesterol concentration in hypothyroid patients and the response to 
thyroxine treatment are strongly correlated with the genotype of the LDL-receptor gene85. In addition, 
hepatic lipase activity is decreased in hypothyroid patients, causing decreased conversion of intermediate-
density lipoproteins (IDL) to LDLs86.  Thyroid hormone further influences fat metabolism by interacting 
with both the lipogenesis and lipolysis processes; the fatty acids derived from adipose tissue are the 
substrate for thyroid hormone-induced calorigenesis87. As lipogenesis serves to maintain fat stores, it is 
stimulated before lipolysis and not simply in response to it; rather, lipogenesis is the result of early 
induction of enzymes in the lipogenic pathway by T3. These enzymes include malic enzyme (malate 
dehydrogenase), glucose 6-phosphate dehydrogenase, and fatty acid synthase88. The expression of the 
genes for these enzymes is also modulated by a high-carbohydrate diet, insulin, and cyclic adenosine 
monophosphate.   
Through its effects on LDL and HDL cholesterol, it is possible that thyroid hormones may also 
lower the risk of atherosclerosis and other cardiovascular diseases. The incidence of atherosclerotic 
vascular disease is directly related to the level of LDL cholesterol89. With the incidence of obesity and its 
co-morbidities, diabetes, metabolic syndrome, and atherosclerotic vascular disease rising at epidemic 
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rates, the utility of compounds capable of treating these diseases would be highly desirable. To date, the 
therapeutic uses of the naturally occurring thyroid hormone have been limited by the adverse side effects 
associated with hyperthyroidism, especially cardiovascular toxicity26.   An increase or a decrease in T3 
action may be beneficial in several cardiac conditions. Reversal of heart failure after intravenous T3 
administration has been reported in a patient with hypothyroidism90. In euthyroid patients undergoing 
cardiac surgery, administration of T3 may improve cardiac output in the short term and reduce systemic 
and pulmonary vascular resistance91, perhaps as a result of a direct effect of T3 on blood vessels that 
reduces peripheral vascular resistance, probably through an extranuclear mechanism92. The 
antiarrhythmic drug amiodarone antagonizes T3-induced gene expression, and part of its therapeutic effect 
may be mediated by blocking T3 action at the nuclear level93. 
Dietary Supplements and Thyroid Disorders 
 There is an emerging inquiry into the possibility of dietary supplements aiding in thyroid health.  
The utilization of harmless, widely available, over-the-counter supplements could be very beneficial in 
combating thyroid disorders due to the thyroid’s far-reaching biological implications.  Researches with an 
interest in thyroid treatments announced at the 2004 annual meeting of the American Thyroid Association 
in Vancouver that a dietary supplement of selenium significantly reduced thyroid cancer cell growth when 
studied in culture according to research done at the time94. Researchers say that future studies addressing 
the role of selenium in the treatment and prevention of thyroid cancer are warranted based on these 
findings.  The news release published by the American Thyroid Association stated that selenium is an 
essential trace mineral that is involved in multiple enzymatic and cell regulatory roles in the body. It is an 
essential part of many antioxidants and catalysts. Integral to the immune system, selenium 
supplementation has been shown in some studies to decrease the progression of HIV and also reduce the 
risk of developing prostate cancer. The article explains that researchers at Weill Cornell Medical 
College/New York-Presbyterian Hospital in New York City explored selenium’s roll in slowing down the 
progression of cancer using microarray analysis. Working in the lab of Thomas J. Fahey, MD, David J. 
Finley, MD, a clinical research fellow, used an in vitro model of follicular, papillary, and anaplastic 
thyroid cancer in which each cell line was treated with three different doses of selenium. They found that 
growth of all three thyroid cancer cell lines was inhibited by selenium in a dose-dependent manner. They 
also found that selenium works by turning on a group of genes — Growth Arrest and DNA Damage 
inducible genes (GADD) — that function as cell cycle regulators. The article quotes Dr. Finley saying 
that GADD genes modulate growth and division of cells by arresting them in part of the cell cycle which 
causes the cells to no longer have the ability to divide.   
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V. Closing  
Author Commentary 
 Throughout the course of this review on thyroid disorders, I hope I have conveyed the importance 
of the thyroid gland to a healthy body and demonstrated the variety of disciples who have contributed to 
science’s understanding of its function.  Again, this paper did not have the intention of being an 
exhaustive survey of all aspects related to the thyroid, yet, it certainly gives the reader a more than 
adequate introduction into the biophysiology involved with the hypothalamus-pituitary-thyroid hormonal 
axis.  Personally, as a future medical student, the production of this paper has been a rewarding 
experience in that it mirrors the clinical process I will be indoctrinated into – namely, understanding the 
physiological background, determining a course of investigation, analyzing results of testing,  utilizing 
existing pharmacological options, and staying familiar with updates in a particular field of medicine.  At 
first I was daunted by the ambitious scope of this paper, but I soon came to realize the reward in seeing 
my ideas and literary investigations materialized in print.  Despite being diagnosed three years ago with 
hypothyroidism, there was still a great deal of information I came across that was new to me and I found 
much of this paper very interesting; further, this project was rewarding because it synthesized real-world 
biology with a spectrum of institutional disciplines so as to produce a rich ‘story’ detailing thyroid 
disorders.  As an undergraduate, it is often difficult within an academic ‘snap-shot’ elective setting to be 
presented with such a wide-ranging representation of a particular issue in medicine.  I am proud to claim 
authorship of this work because of the countless hours put into its production, the details I learned from 
its crafting, and the skills developed that will serve me throughout my medical career. 
 In addition to my hard work, this paper would not have been possible without several people, thus 
a couple of thank-yous are in order.  First, I would like to thank Dr. John Wing of the Boston College 
Biology Department for his advisory role throughout this project.  He allowed me to create this alternative 
project while many of my academic peers were writing on their lab work.  I am grateful for the 
opportunity to pursue other extracurricular endeavors outside of a lab without having to worrying about 
lab-related work upon which to write my senior thesis.  Further, it was a pleasure getting to know Dr. 
Wing outside of the classroom, being one of his Introductory Biology teaching assistants, and being 
academically challenged in his classes.  Second, I would like to thank my parents, Frank and Ann, for 
their endless encouragement throughout my education and providing me with every opportunity I could 
have asked for so as to achieve my goals.  Finally, I would like to thank my private physician, Dr. Adam 
Lauer, D.O., for diagnosing my hypothyroidism over winter break of freshman year.  Without you, I 
never would have written a paper about thyroid disorders…and, I’d still be incorrigibly tired because my 
thyroid was misbehaving!  Thank you. 
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VI. Figures and Diagrams 
 
Figure 1. Schematic Illustration of the Thyroid Gland. 
Courtesy of MayoClinic.com 
 
 
Figure 2. Hormonal Feedback Mechanisms of the Hypothalamus, Pituitary, Thyroid axis 
Courtesy of ABC Health & Wellbeing Online 
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Figure 3.  Gross Specimen of the Thyroid Gland surrounding the Trachea. 
Courtesy of University of Utah School of Medicine 
 
 
Figure 4.  Histological Preparation of Thyroid Tissue Specimen (note: cuboidal epithelium surrounding colloid) 
Courtesy of R. Bowen of Colorado State University 
 
 
Figure 5.  Graves’ ophthalmopathy. 
Courtesy of Harvard Health Publications 
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Figure 6. Diagram of steps in thyroid hormone synthesis. 
“This diagram depicts two follicle cells: on in the process of thyroglobulin synthesis (on the left) and the other in the 
process of thyroglobulin resorption (on the right).  The numbers […] indicate the sequential steps that occur: 1, 
synthesis and secretion of thyroglobulin; 2, uptake and concentration of iodide from the blood, oxidation to iodine, 
ad release into the colloid; 3, iodination of  thyroglobulin in the colloid; 4, formation of T3 and T4 hormones in the 
colloid by oxidative coupling reactions; 5, resorption of colloid by receptor-mediated endocytosis; and 6, release of 
T3 and T4  from the cell into the circulation.” 
Courtesy of Pawlina and Ross. Histology, A Text and Atlas 
 
 42
 
Figure 7. Formation of Thyroxine (T4) from Tyrosine (note: the red ‘I’s indicate iodine atoms) 
Courtesy of Guyton and Hall. Textbook of Medical Physiology. 11th Edition. 
 
 
 
Figure 8. Percentage of Households with Access to Iodized Salt as part of normal dietary uptake. 
Courtesy of the International Council for the Control of Iodine Deficiency Disorders 
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Figure 9.  Triiodothyronine (T3) 
Courtesy of www.biopsychiatry.com 
 
 
Figure 10. Thyroxine (T4) 
Courtesy of www.biopsychiatry.com 
 
 
Figure 11. Thyroid hormone activation of target cells. 
Courtesy of Guyton and Hall. Textbook of Medical Physiology. 11th Edition. 
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Figure 12. Gene schematic for thyroid gene. 
Courtesy of R. Bowen of Colorado State University 
 
 
Figure 13. Model for activation and repression by thyroid hormone receptor 
Courtesy of Jinsong Zhang and Mitchell A. Lazar 
Departments of Medicine, Biochemistry, and Genetics, and the Penn Diabetes Center, 
University of Pennsylvania School of Medicine 
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